Compare Menicon Co., Ltd. with Similar Stocks
Dashboard
1
With ROCE of 8.10%, it has a fair valuation with a 1.31 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 55.43%, its profits have risen by 7.5% ; the PEG ratio of the company is 2.7
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 125,659 Million (Small Cap)
20.00
NA
0.00%
0.38
7.23%
1.34
Revenue and Profits:
Net Sales:
31,673 Million
(Quarterly Results - Mar 2026)
Net Profit:
-432 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.74%
0%
-2.74%
6 Months
6.51%
0%
6.51%
1 Year
55.43%
0%
55.43%
2 Years
29.48%
0%
29.48%
3 Years
-32.22%
0%
-32.22%
4 Years
-47.47%
0%
-47.47%
5 Years
-78.15%
0%
-78.15%
Menicon Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.93%
EBIT Growth (5y)
5.90%
EBIT to Interest (avg)
22.66
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.77
Tax Ratio
39.68%
Dividend Payout Ratio
37.83%
Pledged Shares
0
Institutional Holding
0.22%
ROCE (avg)
12.03%
ROE (avg)
8.53%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.43
EV to EBIT
16.19
EV to EBITDA
8.34
EV to Capital Employed
1.31
EV to Sales
1.37
PEG Ratio
2.70
Dividend Yield
NA
ROCE (Latest)
8.10%
ROE (Latest)
7.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.22%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
31,673.00
32,452.00
-2.40%
Operating Profit (PBDIT) excl Other Income
4,538.00
6,513.00
-30.32%
Interest
199.00
206.00
-3.40%
Exceptional Items
-2,100.00
0.00
Consolidate Net Profit
-432.00
3,197.00
-113.51%
Operating Profit Margin (Excl OI)
39.00%
118.10%
-7.91%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -2.40% vs 3.92% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -113.51% vs 47.87% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
125,605.00
121,491.00
3.39%
Operating Profit (PBDIT) excl Other Income
21,053.00
18,502.00
13.79%
Interest
810.00
751.00
7.86%
Exceptional Items
-2,085.00
-175.00
-1,091.43%
Consolidate Net Profit
5,919.00
5,624.00
5.25%
Operating Profit Margin (Excl OI)
81.50%
82.70%
-0.12%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 3.39% vs 4.56% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 5.25% vs 23.85% in Mar 2025
About Menicon Co., Ltd. 
Menicon Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






